PI3K Inhibitor Delays Progression in Advanced HR-Positive Breast Cancer

Treatment with buparlisib in combination with endocrine therapy significantly improved PFS compared with placebo in patients with HR-positive advanced breast cancer that had progressed after treatment with everolimus plus exemestane.

Source: CancerNetwork - December 8, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Conferences/SABCS 2016 Source Type: news